Zhulun Wang
Research Subjects
Research Interests
Zhulun Wang has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
Sheree Johnstone
§Department of Cardiometabolic Disorders, Amgen Discovery Research, Amgen Inc., South San Francisco, California 94080
8 shared publicationsXiaoshan Min
RemeGen Biosciences, Inc. , 650 Gateway Blvd, Suite 110, South San Francisco, CA 94080
8 shared publicationsNigel Walker
Department of Therapeutic Discovery, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
6 shared publicationsAthena Sudom
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
4 shared publicationsHaoda Xu
Department of Therapeutic Discovery, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
4 shared publicationsStephen Thibault
§Department of Cardiometabolic Disorders, Amgen Discovery Research, Amgen Inc., South San Francisco, California 94080
4 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 9 (3) , 248-258
TROP2 antibody–drug conjugate: unique epitope engagement drives differentiated efficacy
Background: Trophoblast cell surface antigen 2 (TROP2) is frequently overexpressed in various cancers and is associated with poor prognosis. While TROP2-targeted antibody–drug conjugates (ADCs), such as sacituzumab govitecan, sacituzumab tirumotecan, and datopotamab deruxtecan (DXD), achieved clinical success, the mechanisms underlying resistance to these therapies remain incompletely understood. Consequently, the full therapeutic potential of TROP2 ADCs has yet to be comprehended. Methods: We developed R7059-DXD, a novel TROP2-targeted ADC featuring an antibody that binds an epitope that is distinct from those recognized by sacituzumab and datopotamab. The structural basis of epitope recognition was elucidated using cryo-electron microscopy (cryo-EM), complemented by binding affinity analyses across multiple surface-expressed TROP2 variants. Functional activity was systematically evaluated through in vitro antibody-dependent cellular cytotoxicity (ADCC) assays, in vitro ADC-mediated killing assays, and in vivo efficacy studies in tumor models, including resistant lines. Results: The R7059 antibody exhibited high binding affinity across multiple TROP2 variants, addressing a key resistance mechanism. The cryo-EM structure analysis revealed that the R7059 epitope lies in the N-terminal domain of TROP2 and is distinct from the sacituzumab and datopotamab epitopes. Functionally, R7059 demonstrated potent antitumor activity through both ADCC-dependent and independent mechanisms, suggesting additional signaling effects. The R7059 ADC demonstrated robust efficacy in multiple preclinical tumor models, including those resistant to approved TROP2 ADCs. Conclusions: R7059-DXD is a differentiated, epitope-distinct TROP2-targeted ADC with the potential to overcome resistance to existing therapies. These findings support its further clinical development as a novel treatment for TROP2-expressing malignancies, including in patients previously treated with sacituzumab- or datopotamab-based regimens.
- 27 April 2026
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 9 (3) , 248-258
Open AccessTROP2 antibody–drug conjugate: unique epitope engagement drives differentiated efficacy
Background: Trophoblast cell surface antigen 2 (TROP2) is frequently overexpressed in various cancers and is associated with poor prognosis. While TROP2-targeted antibody–drug conjugates (ADCs), such as sacituzumab govitecan, sacituzumab tirumotecan, and datopotamab deruxtecan (DXD), achieved clinical success, the mechanisms underlying resistance to these therapies remain incompletely understood. Consequently, the full therapeutic potential of TROP2 ADCs has yet to be comprehended. Methods: We developed R7059-DXD, a novel TROP2-targeted ADC featuring an antibody that binds an epitope that is distinct from those recognized by sacituzumab and datopotamab. The structural basis of epitope recognition was elucidated using cryo-electron microscopy (cryo-EM), complemented by binding affinity analyses across multiple surface-expressed TROP2 variants. Functional activity was systematically evaluated through in vitro antibody-dependent cellular cytotoxicity (ADCC) assays, in vitro ADC-mediated killing assays, and in vivo efficacy studies in tumor models, including resistant lines. Results: The R7059 antibody exhibited high binding affinity across multiple TROP2 variants, addressing a key resistance mechanism. The cryo-EM structure analysis revealed that the R7059 epitope lies in the N-terminal domain of TROP2 and is distinct from the sacituzumab and datopotamab epitopes. Functionally, R7059 demonstrated potent antitumor activity through both ADCC-dependent and independent mechanisms, suggesting additional signaling effects. The R7059 ADC demonstrated robust efficacy in multiple preclinical tumor models, including those resistant to approved TROP2 ADCs. Conclusions: R7059-DXD is a differentiated, epitope-distinct TROP2-targeted ADC with the potential to overcome resistance to existing therapies. These findings support its further clinical development as a novel treatment for TROP2-expressing malignancies, including in patients previously treated with sacituzumab- or datopotamab-based regimens.
- Open Access
- 17 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (25) , eabb1989
Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition
Details of intestinal sterol absorption and inhibition by cholesterol-lowering drug are uncovered in new protein structures.
- 17 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (25) , eabb1989
Open AccessCryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition
Details of intestinal sterol absorption and inhibition by cholesterol-lowering drug are uncovered in new protein structures.
- Open Access
- 1 February 2020
- Published by Elsevier in Cell Reports
- Vol. 30 (6) , 1714-1723.e6
Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab)
- 1 February 2020
- Published by Elsevier in Cell Reports
- Vol. 30 (6) , 1714-1723.e6
Open AccessMolecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab)
- Open Access
- 12 January 2020
- Published by Taylor & Francis in mAbs
- Vol. 12 (1) , 1710047
Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone involved in regulating glucose and lipid metabolism. GIP receptor (GIPR) antagonism is believed to offer therapeutic potential for various metabolic diseases. Pharmacological intervention of GIPR, however, has limited success due to lack of effective antagonistic reagents. Previously we reported the discovery of two mouse anti-murine GIPR monoclonal antibodies (mAbs) with distinctive properties in rodent models. Here, we report the detailed structural and biochemical characterization of these two antibodies, mAb1 and mAb2. In vitro and in vivo characterizations demonstrated mAb2 is a full GIPR antagonistic antibody and mAb1 is a non-neutralizing GIPR binder. To understand the molecular basis of these two antibodies, we determined the co-crystal structures of GIPR extracellular domain in complex with mAb1 and with mAb2 at resolutions of 2.1 and 2.6 Å, respectively. While the non-neutralizing mAb1 binds to GIPR without competing with the ligand peptide, mAb2 not only partially occludes the ligand peptide binding, but also recognizes the GIPR C-terminal stalk region in a helical conformation that acts as a molecular mimic of the ligand peptide and locks GIPR in a novel auto-inhibited state. Furthermore, administration of mAb2 in diet-induced obesity mice for 7 weeks leads to both reduction in body weight gain and improvement of metabolic profiles. In contrast, mAb1 has no effect on body weight or other metabolic improvement. Together, our studies reveal the unique molecular mechanism of action underlying the superior antagonistic activity of mAb2 and signify the promising therapeutic potential of effective GIPR antagonism for the treatment of metabolic disorders.
- 12 January 2020
- Published by Taylor & Francis in mAbs
- Vol. 12 (1) , 1710047
Open AccessMolecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone involved in regulating glucose and lipid metabolism. GIP receptor (GIPR) antagonism is believed to offer therapeutic potential for various metabolic diseases. Pharmacological intervention of GIPR, however, has limited success due to lack of effective antagonistic reagents. Previously we reported the discovery of two mouse anti-murine GIPR monoclonal antibodies (mAbs) with distinctive properties in rodent models. Here, we report the detailed structural and biochemical characterization of these two antibodies, mAb1 and mAb2. In vitro and in vivo characterizations demonstrated mAb2 is a full GIPR antagonistic antibody and mAb1 is a non-neutralizing GIPR binder. To understand the molecular basis of these two antibodies, we determined the co-crystal structures of GIPR extracellular domain in complex with mAb1 and with mAb2 at resolutions of 2.1 and 2.6 Å, respectively. While the non-neutralizing mAb1 binds to GIPR without competing with the ligand peptide, mAb2 not only partially occludes the ligand peptide binding, but also recognizes the GIPR C-terminal stalk region in a helical conformation that acts as a molecular mimic of the ligand peptide and locks GIPR in a novel auto-inhibited state. Furthermore, administration of mAb2 in diet-induced obesity mice for 7 weeks leads to both reduction in body weight gain and improvement of metabolic profiles. In contrast, mAb1 has no effect on body weight or other metabolic improvement. Together, our studies reveal the unique molecular mechanism of action underlying the superior antagonistic activity of mAb2 and signify the promising therapeutic potential of effective GIPR antagonism for the treatment of metabolic disorders.
- Open Access
- 1 September 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (38) , 14678-14688
Agonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions
- 1 September 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (38) , 14678-14688
Open AccessAgonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions
- Open Access
- 1 August 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (32) , 12634-12646
Molecular basis for the loss-of-function effects of the Alzheimer's disease–associated R47H variant of the immune receptor TREM2
- 1 August 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (32) , 12634-12646
Open AccessMolecular basis for the loss-of-function effects of the Alzheimer's disease–associated R47H variant of the immune receptor TREM2
- Open Access
- 15 May 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 7570
Structure-guided Discovery of Dual-recognition Chemibodies
Small molecules and antibodies each have advantages and limitations as therapeutics. Here, we present for the first time to our knowledge, the structure-guided design of “chemibodies” as small molecule-antibody hybrids that offer dual recognition of a single target by both a small molecule and an antibody, using DPP-IV enzyme as a proof of concept study. Biochemical characterization demonstrates that the chemibodies present superior DPP-IV inhibition compared to either small molecule or antibody component alone. We validated our design by successfully solving a co-crystal structure of a chemibody in complex with DPP-IV, confirming specific binding of the small molecule portion at the interior catalytic site and the Fab portion at the protein surface. The discovery of chemibodies presents considerable potential for novel therapeutics that harness the power of both small molecule and antibody modalities to achieve superior specificity, potency, and pharmacokinetic properties.
- 15 May 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 7570
Open AccessStructure-guided Discovery of Dual-recognition Chemibodies
Small molecules and antibodies each have advantages and limitations as therapeutics. Here, we present for the first time to our knowledge, the structure-guided design of “chemibodies” as small molecule-antibody hybrids that offer dual recognition of a single target by both a small molecule and an antibody, using DPP-IV enzyme as a proof of concept study. Biochemical characterization demonstrates that the chemibodies present superior DPP-IV inhibition compared to either small molecule or antibody component alone. We validated our design by successfully solving a co-crystal structure of a chemibody in complex with DPP-IV, confirming specific binding of the small molecule portion at the interior catalytic site and the Fab portion at the protein surface. The discovery of chemibodies presents considerable potential for novel therapeutics that harness the power of both small molecule and antibody modalities to achieve superior specificity, potency, and pharmacokinetic properties.
- 1 December 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (23) , 5546-5550
Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4
- 1 December 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (23) , 5546-5550
Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4
- 1 July 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (13) , 2885-2891
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4
- 1 July 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (13) , 2885-2891
Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4